Genesis of dihydropyrimidinoneψ calcium channel blockers: Recent progress in structure-activity relationships and other effects

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 1, 2009, Pages 95-106

  Singh, K ^a,a   Arora, D ^a   Singh, S ^a  

^a GURU NANAK DEV UNIVERSITY   (India)

Author keywords

adrenergic receptor antagonists; Calcium channel blockers; Dihydropyridines; Dihydropyrimidines; Dihydropyrimidinones; Mitotic kinesin inhibitors; Structure activity relationships

Indexed keywords

1 BENZYL 4 PIPERIDINYL CARBAMATE; 1,4 DIHYDRO 2,6 DIMETHYL 4 (4 NITROPHENYL) 3,5 PYRIDINEDICARBOXYLIC ACID 3 [3 (4 METHOXYCARBONYL 4 PHENYL 1 PIPERIDINYL)PROPYL]AMIDE 5 METHYLAMIDE; 1,4 DIHYDRO 2,6 DIMETHYL 4 (4 NITROPHENYL) 3,5 PYRIDINEDICARBOXYLIC ACID [3 (4,4 DIPHENYL 1 PIPERIDINYL)PROPYL]AMIDE METHYL ESTER; 1,4 DIHYDROPYRIDINE DERIVATIVE; 2 CHLORO 1,4 DIHYDROPYRIDINE; 3,4 DIHYDROPYRIMIDINONE DERIVATIVE; ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; AMLODIPINE BESYLATE; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE; DIHYDROPYRIDINE DERIVATIVE; DIHYDROPYRIMIDINONE DERIVATIVE; FELODIPINE; MONASTROL; NICARDIPINE; NIFEDIPINE; NIGULDIPINE; NITRENDIPINE; SQ 32547; TETRAHYDROPYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; ADRENERGIC RECEPTOR ALPHA(1A); ALPHA 1 ADRENERGIC RECEPTOR; KINESIN;

ANGINA PECTORIS; ANTIHYPERTENSIVE ACTIVITY; CALCIUM ANTAGONISM; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SYNTHESIS; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; MITOSIS INHIBITION; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; VASODILATATION; CHEMISTRY; DRUG ANTAGONISM; METABOLISM;

CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; KINESIN; RECEPTORS, ADRENERGIC, ALPHA-1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 61349085514     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709787001686     Document Type: Review

References (74)

1. Primrose, S. B.; Twyman, R. Principles of Gene Manipulation and Genomics, Wiley-Blackwell: 2006.
2. Fox, S.; Farr-Jones, S. Yund, M. A. High throughput screening for drug discovery: Continually transitioning into new technology. J. Biomol. Screen., 1999, 4, 183-6.
3. Eisenberg, M. J.; Brox, A.; Bestawros, A. N. Calcium channel blockers: An update. Am. J. Med., 2004, 116, 35-43.
4. Mason, R. P.; Marche, P.; Hintze, T. H. Novel vascular biology of third- generation L-type calcium channel antagonists ancillary actions of Amlodipine. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 2155-63.
5. Cho, H.; Ueda, M.; Shima, K.; Mizuno, A.; Hayashimatsu, M.; Ohnaka, Y.; Takeuchi, Y.; Hamaguchi, M.; Aisaka, K.; Hidaka, T.; Kawai, M.; Takeda, M.; Ishihara, T.; Funahashi, K.; Satoh, F.; Morita, M.; Noguchi, T. Dihydropyrimidines: Novel calcium antagonists with potent and long-lasting vasodilative and antihypertensive activity. J. Med. Chem., 1989, 32, 2399-406.
6. Biginelli, P. Aldureides of ethylic acetoacetate and ethylic oxalacetate. Gazz. Chim. Ital., 1893, 23, 360-416.
7. Kappe, C. O. Biologically active dihydropyrimidones of the Biginelli-type-a literature survey. Eur. J. Med. Chem., 2000, 35, 1043-52.
8. Dallinger, D.; Kappe, C.O. Creating chemical diversity space by scaffold decoration of dihydropyrimidines. Pure Appl. Chem., 2005, 77, 155-61.
9. Kappe, C. O. 100 years of the Biginelli dihydropyrimidine synthesis. Tetrahedron, 1993, 49, 6937-63.
10. (a) Hantzsch, A. Condensationprodukte aus aldehydammoniak und ketoniartigen verbindungen. Chem. Ber., 1881, 14, 1637-8.
11. (b) Hantzch, A. Ueber die Synthese pyridinartiger Verbindungen aus Acetessigäther und Aldehydammoniak. Just. Leib. Ann. Chem., 1882, 215, 1-82.
12. Triggle, D. J.; Janis, R. A. Calcium channel ligands. Ann. Rev. Pharmacol. Toxicol., 1987, 27, 347-69.
13. (a) Goldmann, S.; Stoltefuss, J. 1,4-Dihydropyridines: Effects of chirality and conformation on the calcium antagonist and calcium agonist activities. Angew. Chem., Int. Ed. Eng., 1991, 30, 1559-78.
14. (b) Stout, D. M.; Meyers, A. I. Recent advances in the chemistry of dihydropyridines. Chem. Revs., 1982, 82, 223-43.
15. (c) Triggle, D. J. 1,4-Dihydropyridines as calcium channel ligands and privileged structures. Cell. Mol. Neurobiol., 2003, 23, 293-303.
16. (d) Lavilla, R. Recent developments in the chemistry of dihydropyridines. J. Chem. Soc., Perkin Trans. 1, 2002, 9, 1141-56.
17. (e) Achiwa, K.; Kato, T. Asymmetric synthesis of optically active 1,4-dihydropyridines as calcium antagonist. Curr. Org. Chem., 1999 3, 77-106.
18. Rovnyak, G. C.; Kimball, S. D.; Beyer, B.; Cucinotta, G.; Di-Marco, J. D.; Gougoutas, J.; Hedberg, A.; Malley, M.; McCarthy, J. P.; Zhang, R.; Moreland, S. Calcium entry blockers and activators: Conformational and structural determinants of dihydropyrimidine calcium channel modulators. J. Med. Chem., 1995, 38, 119-29.
19. Gjorstrup, P.; Harding, H.; Isaksson, R.; Westerlund, C. The enantiomers of the dihydropyridine derivative H 160/51 show opposite effects of stimulation and inhibition. Eur. J. Pharmacol., 1986, 122, 357-61 and references cited therein.
20. Buhler, F. R.; Hukthen, U. L.; Kiowski, W.; Muller, F. B.; Bolli, P. The place of the calcium antagonist verapamil in antihypertensive therapy. J. Cardiovasc. Pharmacol., 1982, 4, 350-7.
21. 2+ entry directly activates contraction in frog heart. Nature (London), 1983, 304, 635-8.
22. Cho, H.; Ueda, M.; Mizuno, A.; Ishihara, T.; Aisaka, K.; Noguchi, T. Synthesis of novel 2-chloro-1,4-dihydropyridines by chlorination of 2-hydroxy-1,4-dihydropyridines with phosphorous oxychloride. Chem. Pharm. Bull., 1989, 37, 2117-21.
23. McKinstry, D.W.; Reading, E. H. Synthesis of ethyl esters of some 2-oxo-and 2-thio-1,2,3,4-tetrahydro-5- pyrimidinecarboxylic acids. J. Franklin Inst., 1944, 237, 203-5.
24. Hurst, E. W.; Hull, R. Two new synthetic substances active against viruses of the psittacosis- lymphogranulomatrachoma group. J. Med. Pharm. Chem., 1961, 3, 215-29.
25. Khanina, E. L.; Siliniece, G.; Ozols, J.; Duburs, G.; Kimenis, A. Synthesis and pharmacological studies of some 1,2,3,4-tetrahydropyrimidine-5-carboxylic acid derivatives. Khim-Farm. Zh., 1978, 12, 72-4.
26. (a) Cho, H.; Shima, K.; Hayashimatsu, M.; Ohnaka, Y.; Mizuno, A.; Takeuchi, Y. Synthesis of novel dihydropyrimidines and tetrahydropyrimidines. J. Org. Chem., 1985, 50, 4227-30.
27. (b) Cho, H.; Takeuchi, Y.; Ueda, M.; Mizuno. A. Regioselective synthesis of N-substituted dihydropyrimidin-2(1H) or (3H)-one. Tetrahedron Lett., 1988, 29, 5405-8.
28. Atwal, K. S.; Rovnyak, G. C.; Schwartz, J.; Moreland, S.; Hedberg, A.; Gougoutas, J. Z.; Malley, M. F.; Floyd, D. M. Dihydropyrimidine calcium channel blockers: 2-heterosubstituted 4-aryl-1,4-dihydro-6-methyl-5-pyrimidine carboxylic acid esters as potent mimics of dihydropyridines. J. Med. Chem., 1990, 33, 1510-5.
29. (a) Kastron, V. V.; Vitolin, R. A.; Khanina, E. L.; Duburs, G.; Kimenis, A. Fluorine- containing derivatives of 1,2,3,4-tetrahydropyrimidines: synthesis and pharmacological activity. Khim.-Farm. Zh., 1987, 21, 948-52.
30. (b) Vitolina, R.; Kimenis, A. Effects of tetrahydropyrimidine derivatives on the cardiovascular system. Khim.-Farm. Zh., 1989, 23, 285-7.
31. (a) Atwal, K. S.; Rovnyak, G. C.; O'Reilly, B. C.; Schwartz, J. Substituted 1,4-dihydropyrimidines. 3. Synthesis of selectively functionalized 2- hetero-1,4-dihydropyrimidines. J. Org. Chem., 1989, 54, 5898-907.
32. (b) O'Reilly, B. C.; Atwal, K. S. Synthesis of substituted 1,2,3,4-tetrahydro-6-methyl-2-oxo-5-pyrimidinecarboxylic acid esters: The Biginelli condensation revisited. Heterocycles, 1987, 26, 1185-8.
33. (c) Atwal, K. S.; O'Reilly, B. C.; Gougoutas, J. Z.; Malley, M. F. Synthesis of substituted 1,2,3,4-tetrahydro-6-methyl-2-thioxo-5-pyrimidinecarboxylic acid esters. Heterocycles, 1987, 26, 1189-92.
34. Atwal, K. S.; Rovnyak, G. C.; Kimball, S. D.; Floyd, D. M.; Moreland, S.; Swanson, B. N.; Gougoutas, J. Z.; Schwartz, J.; Smillie, K. M.; Malley, M. F. Dihydropyrimidine calcium channel blockers. 2. 3-Substituted-4-aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic acid esters as potent mimics of dihydropyridines. J. Med. Chem., 1990, 33, 2629-35.
35. Atwal, K. S; Swanson, B. N.; Unger, S. E.; Floyd, D. M.; Moreland, S.; Hedberg, A.; O'Reilly, B. C. Dihydropyrimidine calcium channel blockers. 3. 3-carbamoyl-4-aryl-1,2,3,4-tetrahydro-6-methyl-5-pyrimidinecarboxylic acid esters as orally effective antihypertensive agents. J. Med. Chem., 1991, 34, 806-11.
36. Rovnyak, G. C.; Atwal, K. S.; Hedberg, A.; Kimball, S. D.; Moreland, S.; Gougoutas, J. Z.; O'Reilly, B. C.; Schwartz, J.; Malley, M. F. Dihydropyrimidine calcium channel blockers. 4. Basic 3-substituted-4-aryl-1,4-dihydropyrimidine-5-carboxylic acid esters. Potent antihypertensive agents. J. Med. Chem., 1992, 35, 3254-63.
37. Atwal, K. S.; Moreland, S. Dihydropyrimidine calcium channel blockers. 5: Bicyclic dihydropyrimidines as potent mimics of dihydropyridines. Bioorg. Med. Chem. Lett., 1991, 1, 291-4.
38. Yarim, M.; Sarac, S.; Ertan, M.; Batu, O.; Erol, K. Synthesis, structural elucidation and pharmacological properties of some 5-acetyl-3,4-dihydro-6-methyl-4-(substituted phenyl)-2(1H)- pyrimidinones. IL Farmaco, 1999, 54, 359-63.
39. Yarim, M.; Sarac, S.; Kilic, F. S., Erol, K. Synthesis and in vitro calcium antagonist activity of 4-aryl-7,7-dimethyl/ 1,7,7-trimethyl-1,2,3,4,5,6,7,8 octahydroquinazoline-2,5-dione derivatives. IL Farmaco, 2003, 58, 17-24.
40. Zorkun, I. S.; Sarac, S.; Celebi, S.; Erol, K. Synthesis of 4-aryl-3,4-dihydropyrimidin-2(1H)-thione derivatives as potential calcium channel blockers. Bioorg. Med. Chem., 2006, 14, 8582-9.
41. El-Hamouly, W. S.; El-Khamry, A.-M. A.; Abbas, E. M. H. Synthesis of new 4-aryl-isoxazolo[5,4-d]pyrimidin-6-one(thione) and 4-aryl-pyrazolo[3,4-d]-pyrimidin-6-one derivatives of potential antihypertensive activity. Indian J. Chem. B, 2006, 45B, 2091-8.
42. (a) Singh, K.; Singh, J.; Deb, P. K.: Singh, H. An expedient protocol of the Biginelli dihydropyrimidine synthesis using carbonyl equivalents. Tetrahedron, 1999, 55, 12873-80.
43. (b) Singh, K.; Singh, S.; Mahajan, A. Metalation of Biginelli compounds. A general unprecedented route to C-6 functionalized 4-aryl-3,4-dihydropyrimidinones. J. Org. Chem., 2005, 70, 6114-7.
44. (c) Singh, K.; Singh, S.; Kaur, P. Efficacious preparation of Biginelli compounds. A comparative study of different reaction techniques. Lett. Org. Chem., 2006, 3, 201-3.
45. (d) Singh, K.; Arora, D.; Singh, S. Dowex promoted general synthesis of N,N'-disubstituted-4- aryl-3,4-dihydropyrimidinones using a solvent-free Biginelli condensation protocol. Tetrahedron Lett., 2006, 47, 4205-7.
46. (e) Singh, K.; Singh, S. A mild and practical method for the regioselective synthesis of N-acylated 3,4-dihydropyrimidin-2-ones. New acyl transfer reagents. Tetrahedron Lett., 2006, 47, 8143-6.
47. (f) Singh, K.; Arora, D.; Singh, S. A highly regio- and chemoselective addition of carbon nucleophiles to pyrimidinones. A new route to C4 elaborated Biginelli compounds. Tetrahedron Lett., 2007, 48, 1349-1352.
48. (g) Singh, K.; Singh, S. Unprecedented single-pot protocol for the synthesis of N1, C6-linked bicyclic 3,4-dihydropyrimidinones via lithiation of Biginelli compounds. Tetrahedron, 2008 (doi: 10.1016/j.tet.2008.10.001).
49. (h) Singh, K.; Singh, K. An efficacious protocol for the oxidation of 3,4-dihydropyrimidin-2(1H)-ones using pyridinium chlorochromate as catalyst. Aust. J. Chem., 2008 (10.1071/CH07432).
50. Singh, K.; Arora, D.; Poremsky, E.; Lowery, J.; Moreland, R. S. N1-alkylated 3,4-dihydropyrimidine-2(1H)-ones: Convenient one-pot selective synthesis and evaluation of their calcium channel blocking activity. Eur. J. Med. Chem. 2008, (doi: 10.1016/j.ejmech. 2008.10.002).
51. Compton, D. A. New tools for the antimitotic toolbox. Science, 1999, 286, 913-5.
52. (a) Hamel, E. Antimitotic natural products and their interactions with tubulin. Med. Res. Rev., 1996, 16, 207-31.
53. (b) Jordan, A.; Hadfield, J. A.; Lawrence, N. J.; McGown, A. T. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med. Res. Rev., 1998, 18, 259-96.
54. Mayer, T. U.; Kapoor, T. M.; Haggarty, S. J.; King, R. W.; Schreiber, S. L.; Mitchison, T. J. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science, 1999, 286, 971-4.
55. Cavazzini, A.; Massi, A.; Bergamaschi, G.; Braga, S.; Dondi, F.; Dondoni, A. Combining synthetic and analytical strategies for preparative HPLC enantioseparation of monastrol racemic mixture. Biotechnol. Prog., 2004, 20, 603-12 and references cited therein.
56. Russowsky, D.; Canto, R. F. S.; Sanches, S. A. A.; D'Oca, M. G. M.; Fatima, A.; Pilli, R. A.; Kohn, L. K.; Antonio, M. A.; de Carvalho, J. E. Synthesis and differential antiproliferative activity of Biginelli compounds against cancer cell lines: Monastrol, oxo-Monastrol and oxygenated analogues. Bioorg. Chem., 2006, 34, 173-82.
57. Haggarty, S. J.; Mayer, T. U.; Miyamoto, D.T.; Fathi, R.; King, R. W.; Mitchison, T. J.; Schreiber, S. L. Dissecting cellular processes using small molecules: identification of colchicine-like, taxol-like and other small molecules that perturb mitosis. Chem. Biol., 2000, 7, 275-86.
58. Klein, E.; DeBonis, S.; Thiede, B.; Skoufias, D. A.; Kozielski, F.; Lebeau, L. New chemical tools for investigating human mitotic kinesin Eg5. Bioorg. Med. Chem., 2007, 15, 6474-88.
59. Dallinger, D.; Kappe, C. O. Rapid preparation of mitotic kinesin Eg5 inhibitor monastrol using controlled microwave-assisted synthesis. Nat. Protoc., 2007, 2, 317-21.
60. Kirby, R. S.; Christmas, T. J. J. Benign Prostatic Hyperplasia, Gower Medical Publishing: London, England, 1993.
61. 1a-adrenergic receptor antagonists. Bioorg. Med. Chem. Lett., 2000, 10, 175-8.
62. 1a adrenoceptor-selective antagonists. 2. Approaches to eliminate opioid agonist metabolites via modification of linker and 4-methoxycarbonyl-4-phenylpiperidine moiety. J. Med. Chem., 1999, 42, 4778-93.
63. (c) Lagu, B.; Tian, D.; Nagarathnam, D.; Marzabadi, M. R.; Wong, W. C.; Miao, S. W.; Zhang, F.; Sun, W.; Chiu, G.; Fang, J.; Forray, C.; Chang, R. S. L.; Ransom, R. W.; Chen, T. B., O' Malley, S.; Zhang, K.; Vyas, K. P.; Gluchowski, C. Design and synthesis of novel..1a adrenoceptor-selective antagonists. 3. Approaches to eliminate opioid agonist metabolites by using substituted phenylpiperazine side chains. J. Med. Chem., 1999, 42, 4794-803.
64. Ashok, M.; Holla, B. S.; Kumari, N. S. Convenient one pot synthesis of some novel derivatives of thiazolo[2,3-bdihydropyrimidinone possessing 4-methylthiophenyl moiety and evaluation of their antibacterial and antifungal activities. Eur. J. Med. Chem., 2007, 42, 380-5.
65. Ghorab, M. M.; Abdel-Gawad, S. M.; El-Gaby, M. S. A. Synthesis and evaluation of some new fluorinated hydroquinazoline derivatives as antifungal agents. IL Farmaco, 2000, 55, 249-55.
66. Blackburn, C.; Guan, B.; Brown, J.; Cullis, C.; Condon, S. M.; Jenkins, T. J.; Peluso, S.; Ye, Y.; Gimeno, R. E.; Punreddy, S.; Sun, Y.; Wu, H.; Hubbard, B.; Kaushik, V.; Tummino, P.; Sanchetti, P.; Sun, D.Y.; Daniels, T.; Tozzo, E.; Balani, S. K.; Raman, P. Identification and characterization of 4-aryl-3,4-dihydropyrimidin-2(1H)-ones as inhibitors of fatty acid transporter FATP4. Bioorg. Med. Chem. Lett., 2006, 16, 3504-9.
67. Blacquiere, J. M.; Sicora, O.; Vogels, C. M.; Cuperlovic-Culf, M.; Decken, A.; Ouellette, R. J.; Westcott, S. A. Dihydropyrimidinones containing boronic acids. Can. J. Chem., 2005, 83, 2052-9.
68. Stefani, H. A.; Oliveira, C. B.; Almeida, R. B.; Pereira, C. M. P.; Braga, R. C.; Cella, R.; Borges, V. C.; Savegnago, L.; Nogueira, C. W. Dihydropyrimidin-(2H)-ones obtained by ultrasound irradiation: a new class of potential antioxidant agents. Eur. J. Med. Chem., 2006, 41, 513-8.
69. Matthews, J. M.; Liotta, F.; Hageman, W.; Rivero, R. A.; Westover, L.; Yang, M.; Xu, J.; Demarest, K. Discovery of a dihydropyrimidine series of molecules that selectively mimic the biological actions of calcitonin. Bioorg. Med. Chem. Lett., 2004, 14, 1155-9.
70. Wisen, S.; Androsavich, J.; Evans, C. G.; Chang, L.; Gestwicki, J. E. Chemical modulators of heat shock proteins 70 (Hsp70) by sequential, microwave-accelerated reactions on solid phase. Bioorg. Med. Chem. Lett., 2008, 18, 60-5.
71. Wright, C. M.; Chovatiya, R. J., Jameson, N. E.; Turner, D. M.; Zhu, G.; Werner, S.; Huryn, D. M.; Pipas, J. M.; Day, B. W.; Wipf, P.; Brodsky, J. L. Pyrimidinone-peptoid hybrid molecules with distinct effects on molecular chaperone function and cell proliferation. Bioorg. Med. Chem., 2008, 16, 3291-301.
72. Sujatha, K.; Shanmugam, P.; Perumal, P. T.; Muralidharan, D.; Rajendran, M. Synthesis and cardiac effects of 3,4-dihydropyrimidin-2-(1H)-one-5 carboxylates. Bioorg. Med. Chem. Lett., 2006, 16, 4893-7.
73. Kumar, R.; Mittal, A.; Ramachandran, U. Design and synthesis of 6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid derivatives as PPARγ activators. Bioorg. Med. Chem. Lett., 2007, 17, 4613-8.
74. Kheder, N., A.; Mabkhot, Y. N.; Farag, A. M. Synthesis and antimicrobial evaluation of some new pyrimidine derivatives. Heterocycles, 2008, 75, 887-97.